Custom Health Delivers US$51.6 Million Proforma Annualized Revenue Run-Rate in Q1-2026

Custom Health’s Q1 2026 revenue rose 5% to US$4.3M (vs. US$4.1M) and gross margin improved 380 bps to 48.6%, but the company’s Adjusted EBITDA loss widened to US$5.3M from US$3.0M and IFRS net loss increased to US$8.5M. The firm also completed its TSX listing as CHLT on June 24, 2026 and secured capital structure support of up to ~US$50M in newly secured financing facilities with over US$35M undrawn. Additionally, it acquired InnovativeRx operating assets in a ~US$16.55M cash-and-equity deal expected to add ~US$34.3M annualized revenue and US$2.53M annualized EBITDA to support growth.

Analysis

This is a liquidity event before it is a fundamental re-rating. The business is still early in the cash-conversion curve: reported growth is being purchased with acquisition capital, while consolidated losses indicate the equity story depends on integration discipline and reimbursement stability rather than top-line momentum alone. In that setup, the market usually overweights the listing and underweights the dilution cycle that often follows when roll-ups lean on convertibles and secured facilities.

The nearest-term winners are the financing providers and any small, fragmented pharmacy assets that can be rolled into the platform at low purchase multiples; the likely losers are standalone regional operators that lose referral flow or become acquisition targets at compressed valuations. A second-order risk is that every incremental deal increases compliance, working-capital, and integration complexity faster than the revenue base grows, which can keep the multiple anchored even if headline revenue inflects. For the sector, this can reset expectations for other healthcare roll-ups: growth investors may start demanding visible operating cash flow, not just pro forma run-rate claims.

Over the next 1-3 months, the stock should trade more on float dynamics and financing optics than on operating performance. The main falsifier for a bearish stance is a clean first public quarter with consolidated EBITDA improving and no need for additional equity; the main tail risk is an acquisition announcement financed with stock that reignites dilution concerns. If management can show retention of acquired patients and a faster-than-expected margin step-up, the name could become a momentum small-cap; otherwise this is likely a tradeable story, not yet an investable compounder.

Key Decisions for Investors

• Do not chase CHLT in the first 2-4 weeks post-listing; wait for trading to normalize and for the first public-quarter filing to verify whether adjusted EBITDA burn is narrowing.
• If CHLT rallies more than 20% above the recent financing/listing reference on weak volume, consider a small tactical short or put-spread position for 1-2 months; the risk/reward favors fading a float-driven move with dilution still overhanging.
• Only initiate a long CHLT after evidence of consolidated cash flow improvement and post-acquisition retention; use the next quarterly update as the trigger, and cut the thesis if losses widen or another equity-funded deal is announced.
• Set an alert for any new acquisition terms: debt-funded deals are neutral-to-positive, but equity-heavy financing would be a bearish signal for CHLT’s multiple and could compress the shares quickly.